In this Healio Video Perspective from the Retina Society meeting, David A. Eichenbaum, MD, of Retina Vitreous Associates of Florida, presents promising 12-month results from the DAVIO 2 trial.
The study, the largest intravitreal tyrosine kinase inhibition trial to date, is investigating two doses of EYP-1901 (vorolanib, EyePoint Pharmaceuticals) for wet age-related macular degeneration vs. aflibercept 2 mg. Overall, a single injection of EYP-1901 demonstrated maintenance of visual acuity and reduced treatment burden, according to Eichenbaum.
“These results are encouraging,” he said. “They